ReviewClinical infectious diseases : an official publication of the Infectious Diseases Society of America2018
Carbapenemase-Producing Organisms: A Global Scourge.
Review in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06811727 (CONTinuous Infusion Versus Intermittent Dosing of ceftaZidime/AVIbactam in Critically Ill Patients With Klebsiella Pneumoniae OXA-48 or Pseudomonas Aeruginosa Infections), which is not on this map. Cited by 351 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
CONTinuous Infusion Versus Intermittent Dosing of ceftaZidime/AVIbactam in Critically Ill Patients With Klebsiella Pneumoniae OXA-48 or Pseudomonas Aeruginosa Infections: A Single-centre Randomized Open-label Trial (ZAVICONT)
Who cites it
351 citing papers in PubMed, 2 syntheses or guidelines pooled it, 627 citations in OpenAlex.
- Availability and Key Characteristics of National Early Warning Systems for Emerging Profiles of Antimicrobial Resistance in High-Income Countries: Systematic Review.JMIR public health and surveillance · 2025Pooled it
- A systematic review and meta-analysis of carbapenem-resistant Enterobacteriaceae in West Africa.BMC medical genomics · 2024Pooled it
- Prevalence of antimicrobial-resistantOne health (Amsterdam, Netherlands) · 2026Article
- Acquired carbapenemase-producing organisms in North London: health inequalities and healthcare associations, 2016-2023.JAC-antimicrobial resistance · 2026Article
- Prevalence and molecular typing of carbapenem-resistant Enterobacterales in a secondary-care hospital in Jazan region, Saudi Arabia.New microbes and new infections · 2026Article
- The PRECISE framework: a structured approach to antibiogram interpretation for antimicrobial optimization at the bedside.Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia · 2026Review
- Chelate-conjugated β-lactams resensitize metallo-β-lactamase IMP-1-producing gram-negative bacteria against carbapenem antibiotics.Microbiology spectrum · 2026Article
- Carbapenem-Resistant Enterobacterales (CRE) in Europe: Surveillance Challenges, Emerging Threats and Public Health Preparedness.Antibiotics (Basel, Switzerland) · 2026Review
- Environmental factors modulate β-lactamase phenotypes: effect of pH and redox potential on β-lactam resistance.Microbiology spectrum · 2026Article
- Evaluation of BD Phoenix CPO Detect and NG-Test CARBA 5 for the detection and classification of carbapenemase-producingMicrobiology spectrum · 2026Article
- In Vitro Activity of Imipenem-Funobactam Against Clinical Isolates of Gram-Negative Bacilli.Antibiotics (Basel, Switzerland) · 2026Article
- Carbapenemase-Producing Enterobacterales in Pets: A New Threat From Veterinary Clinics.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2026Article
- [Clinical and practical aspects of multidrug-resistant pathogens].Urologie (Heidelberg, Germany) · 2026Review
- Evaluation of a Novel In Vitro Diagnostic Immunoassay for the Rapid Qualitative Detection of KPC, NDM, OXA-48-like, IMP and VIM Carbapenemases.Diagnostics (Basel, Switzerland) · 2026Article
- Phenotype-Guided Nanotherapeutic Strategies for Carbapenem-ResistantPharmaceutics · 2026Review
- National genomic surveillance reveals global plasmid and chromosomal dissemination routes of blanpj antimicrobials and resistance · 2026Article
- Article
- Advances in CRISPR-Cas for Diagnosis and Treatment ofPathogens (Basel, Switzerland) · 2026Review
- Healthcare-associated infections and antimicrobial resistance in Canadian acute care hospitals, 2020-2024.Canada communicable disease report = Releve des maladies transmissibles au Canada · 2026Article
- DOTA-grafted Cationic Polymers Behaving as Powerful Macromolecular Resistance-reversal Agents (MRRAs) Combating Against New Delhi Metallo-β-lactamase (NDM)-producing Bacteria.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
291 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 7 institutions in 3 countries.
Funding
Abstract
The dramatic increase in the prevalence and clinical impact of infections caused by bacteria producing carbapenemases is a global health concern. Carbapenemase production is especially problematic when encountered in members of the family Enterobacteriaceae. Due to their ability to readily spread and colonize patients in healthcare environments, preventing the transmission of these organisms is a major public health initiative and coordinated international effort are needed. Central to the treatment and control of carbapenemase-producing organisms (CPOs) are phenotypic (growth-/biochemical-dependent) and nucleic acid-based carbapenemase detection tests that identify carbapenemase activity directly or their associated molecular determinants. Importantly, bacterial isolates harboring carbapenemases are often resistant to multiple antibiotic classes, resulting in limited therapy options. Emerging agents, novel antibiotic combinations and treatment regimens offer promise for management of these infections. This review highlights our current understanding of CPOs with emphasis on their epidemiology, detection, treatment, and control.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.